223 related articles for article (PubMed ID: 34259584)
1. Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA.
Shelbaya A; Kelton JM; Thompson J; Alvir JM; Maculaitis MC; Yang J
Future Oncol; 2021 Oct; 17(30):3941-3950. PubMed ID: 34259584
[TBL] [Abstract][Full Text] [Related]
2. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.
Gulácsi L; Brodszky V; Baji P; Rencz F; Péntek M
Adv Ther; 2017 May; 34(5):1128-1144. PubMed ID: 28397080
[TBL] [Abstract][Full Text] [Related]
3. Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany.
Otremba B; Borchardt J; Kuske A; Hollnagel-Schmitz M; Losch FO
Future Oncol; 2020 May; 16(15):1001-1012. PubMed ID: 32286864
[No Abstract] [Full Text] [Related]
4. Rituximab reference vs biosimilar utilization for oncology vs nononcology indications.
Labdi BA; Elbeshbeshy RA; Winkler M; Johnson SG; Attridge RL
Am J Manag Care; 2023 Nov; 29(11):e353-e356. PubMed ID: 37948656
[TBL] [Abstract][Full Text] [Related]
5. The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.
Brown JR; Cymbalista F; Sharman J; Jacobs I; Nava-Parada P; Mato A
Oncologist; 2018 Mar; 23(3):288-296. PubMed ID: 29212732
[TBL] [Abstract][Full Text] [Related]
6. The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe.
Bishton M; Marshall S; Harchowal J; Salles G; Golfier C; Tucci A; Fernández AR; Sanchez Blanco JJ; Bocchia M; Kim S; Lee YN; Zinzani PL
Hematol Oncol; 2022 Aug; 40(3):370-380. PubMed ID: 35168291
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
Lee S; Lee H; Kim E
BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
[TBL] [Abstract][Full Text] [Related]
8. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
Ogura M; Coiffier B; Kwon HC; Yoon SW
Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
[TBL] [Abstract][Full Text] [Related]
9. Safety of switching between rituximab biosimilars in onco-hematology.
Urru SAM; Spila Alegiani S; Guella A; Traversa G; Campomori A
Sci Rep; 2021 Mar; 11(1):5956. PubMed ID: 33727667
[TBL] [Abstract][Full Text] [Related]
10. Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study.
McBride A; Daniel S; Driessen MT; Szende A; Choudhry A; Tian M; Ariely R; Thompson S
Leuk Res; 2021 Dec; 111():106671. PubMed ID: 34530254
[TBL] [Abstract][Full Text] [Related]
11. A descriptive analysis of real-world oncology biosimilar use in Japan.
Roth JA; Rahshenas M; Nowacki G; Masurkar N; Shelbaya A; Tajima K; Dorman S; Ono C
Future Oncol; 2024 Jun; ():1-14. PubMed ID: 38864611
[TBL] [Abstract][Full Text] [Related]
12. CT-P10 (Truxima™): A Rituximab Biosimilar.
Deeks ED
BioDrugs; 2017 Jun; 31(3):275-278. PubMed ID: 28497220
[TBL] [Abstract][Full Text] [Related]
13. Rituximab biosimilars for lymphoma in Europe.
Jurczak W; Długosz Danecka M; Buske C
Expert Opin Biol Ther; 2019 Oct; 19(10):1045-1056. PubMed ID: 31512535
[No Abstract] [Full Text] [Related]
14. A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea.
Jo JC; Jeon Y; Kim D; Yang DH; Lee WS; Choi YS; Yi JH; Yoon DH; Kong JH; Choe JY; Kim S; Ahn K; Park T; Ju H; Kwon S; Cho SG
Expert Opin Biol Ther; 2023; 23(8):737-747. PubMed ID: 36757373
[TBL] [Abstract][Full Text] [Related]
15. Biosimilar monoclonal antibodies (mAbs) in oncology.
Moore C
Br J Nurs; 2017 Sep; 26(16):S26-S32. PubMed ID: 28880625
[TBL] [Abstract][Full Text] [Related]
16. Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database.
Xue X; Qian J
Expert Opin Drug Saf; 2024 May; ():1-10. PubMed ID: 38680112
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
[TBL] [Abstract][Full Text] [Related]
18. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
19. Real-world usage of bevacizumab-bvzr biosimilar in US oncology practice.
Yang J; Kelton JM; Thompson J; Alvir JMJ; Maculaitis MC; Shelbaya A
Am J Manag Care; 2022 Apr; 28(4):160-166. PubMed ID: 35420744
[TBL] [Abstract][Full Text] [Related]
20. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
